Cargando…
Hypophosphataemia, fibroblast growth factor 23 and third-generation intravenous iron compounds: a narrative review
Third-generation intravenous (i.v.) iron preparations are safe and efficacious and are increasingly used in the treatment of iron-deficiency anaemia. Hypophosphataemia is emerging as an established side-effect following the administration of certain compounds. Symptoms of hypophosphataemia can be ma...
Autores principales: | Kassianides, Xenophon, Bhandari, Sunil |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioExcel Publishing Ltd
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7819638/ https://www.ncbi.nlm.nih.gov/pubmed/33519940 http://dx.doi.org/10.7573/dic.2020-11-3 |
Ejemplares similares
-
Patient reported outcome measures and cardiovascular outcomes following high dose modern intravenous iron in non-dialysis dependent chronic kidney disease: secondary analysis of ExplorIRON-CKD
por: Kassianides, Xenophon, et al.
Publicado: (2023) -
The comparative effects of intravenous iron on oxidative stress and inflammation in patients with chronic kidney disease and iron deficiency: a randomized controlled pilot study
por: Kassianides, Xenophon, et al.
Publicado: (2021) -
Correction to: Protocol and baseline data for a prospective open-label explorative randomized singlecenter comparative study to determine the effects of various intravenous iron preparations on markers of oxidative stress and kidney injury in chronic kidney disease (IRON-CKD)
por: Ziedan, Ahmed, et al.
Publicado: (2020) -
Hepatic osteodystrophy with hypophosphataemia and elevated fibroblast growth factor‐23
por: Ng, Nicholas Beng Hui, et al.
Publicado: (2022) -
Markers of Oxidative Stress, Inflammation and Endothelial Function following High-Dose Intravenous Iron in Patients with Non-Dialysis-Dependent Chronic Kidney Disease—A Pooled Analysis
por: Kassianides, Xenophon, et al.
Publicado: (2022)